Kalvista Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs and private third-party payors. It also serves state programs such as Medicaid and other state programs that reimburse items and services. The markets include entities involved in healthcare benefits, items, or services reimbursed under Medicare, Medicaid, or the Children's Health Insurance Program. Specific market segments include federal healthcare benefit programs, private third-party payors, Medicaid, other state programs, and manufacturers of covered drugs, devices, biologics, and medical supplies.
KalVista Pharmaceuticals Unveils New Sebetralstat Data at AAAAI WAO 2025 Joint Congress: Promising Advances in Treating Hereditary Angioedema CAMBRIDGE, Mass. and SALISBURY, England KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced its commitment to advancing the field of hereditary angioedema (HAE) treatment with the presentation of novel findings related to its investigational drug, sebetralstat. The data will be showcased at the American Academy of Allergy, Asthma and Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress, set to be held in San Diego, California, from February 28 to March 3, 2025. This announcement comes as KalVista has confirmed that six abstracts highlig...
KalVista Pharmaceuticals Announces Strategic Expansion with Key Inducement Grants KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a prominent name in the biopharmaceutical industry, recently fortified its team by granting inducement options to two newly-hired employees, in alignment with the company s growth trajectory. On March 3, 2025, the compensation committee of KalVista s board of directors executed this strategic move, showcasing the company s commitment to attracting top-tier talent as it continues to innovate within the sector.These inducement options, which collectively amount to the purchase of 14,000 shares of KalVista common stock, serve as a significant incentive, reinforcing the value of each e...
: KalVista Pharmaceuticals, Inc. has presented new data on sebetralstat at the Bradykinin Symposium 2024, detailing findings from multiple phases of clinical trials. This article summarizes the key outcomes related to efficacy and safety gathered from phase 2 and phase 3 double-blind, placebo-controlled crossover trials, alongside interim results from the KONFIDENT-S extension trial and real-world data. KalVista Pharmaceuticals, based in Cambridge, Massachusetts, and Salisbury, England, continues to advance its innovative approach to treating diseases linked to bradykinin dysregulation. The company recently showcased significant data concerning its investigational drug, sebetralstat, at the Bradykinin Sym...
KalVista Pharmaceuticals, Inc. headquartered in Cambridge, Massachusetts, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat. This investigational drug is a novel oral plasma kallikrein inhibitor developed for the on-demand treatment of hereditary angioedema (HAE) attacks. The acceptance of the NDA marks a significant milestone in the regulatory process and paves the way for potential new therapeutic options for patients affected by HAE.Sebetralstat is designed for use in both adult and pediatric patients aged 12 years and older, addressing a critical need in the management of HAE. This rare genetic condition is characterized b...
KalVista Pharmaceuticals Spearheads Breakthrough Research at 2024 Bradykinin Symposium in Berlin CAMBRIDGE, Mass. and SALISBURY, England Setting a notable milestone in its research trajectory, KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is preparing for a prominent role at the 2024 Bradykinin Symposium in Berlin, Germany. The company has announced the acceptance of six abstracts for presentation, a testament to its pioneering work in the field of hereditary angioedema (HAE) and other bradykinin-mediated disorders. This significant conference will be held from September 5-6, 2024, in the distinguished Kaiserin Friedrich-Haus Lecture Hall.On Friday, September 6, KalVista s research team will unveil its la...
KalVista Pharmaceuticals: Recent Developments in Inducement Grants, New Drug Applications, and Conference Presentations KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Cambridge, Mass. and Salisbury, England KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a company dedicated to the development of novel treatments for hereditary angioedema (HAE) and other diseases, has made several important announcements. On July 1, 2024, the compensation committee of KalVista s board of directors granted twelve newly-hired employees inducement options. These inducement options permit the purchase of an aggregate of 84,000 shares of KalVista common stock. This was done as an induce...
Cambridge, Mass. and Salisbury, England - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a leading pharmaceutical company, has recently announced the initiation of the KONFIDENT-KID clinical trial. The trial aims to evaluate the efficacy and safety of sebetralstat, an innovative oral plasma kallikrein inhibitor, as an on-demand treatment for pediatric patients aged 2 to 11 with hereditary angioedema (HAE). Spanning across North America, Europe, and Asia, this open-label trial intends to enroll approximately 24 children.The KONFIDENT-KID trial will focus on collecting crucial data regarding safety, pharmacokinetics, and efficacy of sebetralstat for each participant. By addressing one of the pressing unmet nee...
KalVista Pharmaceuticals Announces Ten s Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024CAMBRIDGE, Mass. and SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a leading biopharmaceutical company specializing in the development of novel therapies for various allergic and inflammatory diseases, exhilaratingly shared that multiple abstracts and a symposium have been accepted for presentation at the prestigious European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. This significant event, set to be held in Valencia, Spain from May 31 to June 3, will provide an excellent platform for KalVista to showcase their groundbreaking ...
The field of genetic medicine has witnessed remarkable advancements, with innovative pharmaceutical companies pushing boundaries to find effective solutions for genetic diseases. One such company, KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), has taken center stage with its focus on the discovery, development, and commercialization of oral, small molecule protease inhibitors. In this article, we will delve into two recent announcements by KalVista Pharmaceuticals, highlighting their participation in upcoming investor conferences and the significant implications of their cutting-edge research.KalVista Pharmaceuticals at Investor Conferences:On Tuesday, May 28, 2024, KalVista Pharmaceuticals management will ...
KalVista Pharmaceuticals, a leading biopharmaceutical company specializing in the development of novel therapies, has recently unveiled its strategic plans for fiscal year 2025. With its comprehensive approach and groundbreaking investigational drug, sebertralstat, the company aims to revolutionize the on-demand treatment of hereditary angioedema (HAE). This announcement follows a productive year for KalVista, marked by significant accomplishments and groundbreaking advancements.One of the key highlights of KalVista s achievements in 2024 was the positive outcome of its Phase 3 KONFIDENT clinical trial. This pivotal study supported the efficacy and safety of sebertralstat, an oral plasma kallikrein inhibitor...
Kalvista Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including federal healthcare benefit programs and private third-party payors. It also serves state programs such as Medicaid and other state programs that reimburse items and services. The markets include entities involved in healthcare benefits, items, or services reimbursed under Medicare, Medicaid, or the Children's Health Insurance Program. Specific market segments include federal healthcare benefit programs, private third-party payors, Medicaid, other state programs, and manufacturers of covered drugs, devices, biologics, and medical supplies.
Sources:
Kalvista Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kalvista Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kalvista Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
95.84 %